Mid Atlantic Bio Angels

New View Surgical is an emerging medical device company focused on the development and commercialization of the VisionPort™ System, a novel surgical imaging and access system for minimally invasive surgery. The company is led by an experienced team of medical device innovators and commercial experts who have come together to design and commercialize impactful solutions that meet a variety of unmet market needs. The company’s proprietary VisionPort™ system combines multiple imaging and access devices into just one simple, easy-to-use device that is disposable and is expected to bring a variety of clinical and economic advantages to minimally invasive surgery operating rooms around the world.

Seneca is a biotechnology company that focuses on developing novel oncolytic immunotherapeutics and derivatives as cancer therapeutics, cancer vaccines, and vaccines for the treatment of cancer. This oncolytic immunotherapeutic is called Seneca Valley Virus (SVV) which eliminates tumor cells in which it can replicate. Seneca Therapeutics is headquartered in Blue Bell, Pennsylvania.

Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke, TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.

Sana Health is an audio-visual neuromodulation device, that provides anxiety relief on-demand - multiple applications in pain and mental health, 2 pivotal studies are underway in Fibromyalgia (FDA designated breakthrough device) and Neuropathic Pain. Anxiety and PTSD trials starting in Q2 2022, DoD grant for PTSD. SOSV, Founders Fund, Noetic Fund, Harmonix, Dreamit, Esplanade, Bridge Builders Collective, Menlo Ventures.

New View Surgical is an emerging medical device company focused on the development and commercialization of the VisionPort™ System, a novel surgical imaging and access system for minimally invasive surgery. The company is led by an experienced team of medical device innovators and commercial experts who have come together to design and commercialize impactful solutions that meet a variety of unmet market needs. The company’s proprietary VisionPort™ system combines multiple imaging and access devices into just one simple, easy-to-use device that is disposable and is expected to bring a variety of clinical and economic advantages to minimally invasive surgery operating rooms around the world.

Healionics has applied its expertise in synthetic biomaterials to develop a novel vascular graft (artificial blood vessel) that, unlike existing grafts, remains open to blood flow long-term without need for costly interventions. Its first commercial application will be as a more reliable means of vascular access for dialysis patients, with a subsequent application to treat peripheral artery disease. We have great results in multiple controlled animal studies, a large patent portfolio, established production capacity, and are ready to begin human studies later this year in preparation for market launch. Near-Term Problem / Market Opportunity: Vascular Access for Dialysis Kidney failure patients need to have their blood filtered 3 times per week via dialysis. This removes waste from the blood, which would otherwise cause them to die. However, current methods for repeatedly accessing the bloodstream for dialysis are unreliable. This problem is a huge contributor to the $50 billion per year that the U.S. spends on dialysis patients (7% of Medicare’s entire budget!). A vascular graft is often implanted under the skin (connecting an artery to a vein) to create an access site with sufficient bloodflow for dialysis -- but existing grafts tend to occlude quickly, requiring repeated expensive interventions to keep them open. Solution: STARgraft Because our vascular graft remains open to blood flow much longer than existing grafts, it can potentially satisfy a severe unmet clinical need for ready-to-use, safe, long-term dialysis access, while substantially reducing costs, illness and death rate among dialysis patients. Product Pipeline We have additional products in development, including an implantable port which will allow needle-free dialysis. Eliminating the use of needles would further reduce cost and illness among dialysis patients, and allow them to perform dialysis in the convenience of their own home. In addition, our platform STAR biomaterial can improve the performance of a wide range of implantable devices via its remarkable ability to prevent both infection and scar tissue. We currently have two corporate-funded development contracts to explore STAR material’s use in multiple other device applications.

Virion Therapeutics is a science-driven company developing innovative immune-based treatments for virally associated cancers and chronic viral infections. Their vaccines, ChiVax and ChiVax-gD, represent novel and highly effective platforms to induce potently and sustained T cell-mediated immune responses against transformed or infected cells, thereby targets common diseases with unmet medical needs. Each component comprising chimeric vaccine candidates has completed pre-clinical testing that allows for their translation into clinical trials for several different indications. Guided by their scientific and management expertise, these platforms may help cure such devastating diseases as HPV-induced cancers and chronic Hepatitis B infections. Virion Therapeutics was founded in 2018 and is headquartered in Newark, Delaware.

FEMSelect is making a lasting impact on women's health by delivering an innovative technology platform. It is the developer of EnPlace, a minimally invasive and mesh-free system for pelvic floor ligament fixation. Using EnPlace takes approximately 30 minutes. The patented delivery system enables the precise guidance, insertion, and deployment of the anchor unit. The anchor is designed to be introduced through the vaginal wall and secured to the pelvic floor ligament to provide stabilization. FEMSelect was founded in 2012 and is headquartered in Modi’in, Israel.

Elysium Therapeutics is a health care company that focuses on biotechnology, fitness, medical, and robotics. It was founded in 2013 and headquartered in Danville, California.

A biotech company, engages in developing monoclonal antibodies to treat fibrotic and remodeling diseases. The company was founded in 2012 and is headquartered in Bryn Mawr, Pennsylvania .

PainQx is a diagnostic/software company that has developed a next generation approach to objectively measure pain in humans. The PainQx platform achieves this by assessing neural activity from a patient’s brain and processing and decoding the data through proprietary algorithms. The output is a scaled pain and neurological side effects biomarker that is directly correlated to a patient’s pain state. The PainQx system is currently being used as a clinical assessment tool by companies using pain as a primary or secondary clinical end point to measure their drug’s and/or device’s efficacy.

New View Surgical is an emerging medical device company focused on the development and commercialization of the VisionPort™ System, a novel surgical imaging and access system for minimally invasive surgery. The company is led by an experienced team of medical device innovators and commercial experts who have come together to design and commercialize impactful solutions that meet a variety of unmet market needs. The company’s proprietary VisionPort™ system combines multiple imaging and access devices into just one simple, easy-to-use device that is disposable and is expected to bring a variety of clinical and economic advantages to minimally invasive surgery operating rooms around the world.

Genome Profiling, LLC (www.genprollc.com) is at the forefront of this rapidly emerging market with the first epigenetic biomarker discovery platform that combines a proprietary pre-NGS gDNA preparation kit matched to powerful NGS data analytics algorithms that plug-n-play into standard NGS workflows and enable one NGS run to deliver data for both genomic variant call analyses data AND epigenetic data.

Evrys Bio was founded on breakthrough discoveries made at Princeton University. Whereas immuno-oncology drugs engage the patient’s immune system to fight cancer, Evrys Bio antivirals engage the cell’s intrinsic immunity to defend against infection. Evrys Bio’s vision is to develop first-in-class antivirals that are safe, address the problem of acquired drug-resistance, and provide unique broad-spectrum treatment options. This will transform the practice of medicine by addressing the infectious disease condition holistically as opposed to targeting a specific virus-type.

Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines for the treatment of allergy and other human health targets. The company was founded in 2005 and is based in Lancaster, Pennsylvania.

Cerus Endovascular Ltd designs and develops interventional neuroradiology devices and delivery systems. The company develops e-clipse, an aneurysm occlusive device that addresses the current neurovascular aneurysm procedures attempted by surgical clipping, minimally invasive metal coils and liquid embolics. The company was founded in 2011 and is based in Oxford, United Kingdom.